The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...